Bausch Health approval of Bryhali largely expected, says Wells Fargo

Bausch Health announced this morning that final approval of Bryhali Lotion for the treatment of plaque psoriasis in adults is pending the expiration of exclusivity for a related product, which is expected to occur in early November, Wells Fargo analyst David Maris tells investors in a research note. The analyst reiterates his belief that the market largely expected Bausch would receive approval for Bryhali since the active ingredient is already available as a generic and other similar products are already approved using this active ingredient. While unaware the approval would be held up based on the exclusivity of another product, Maris does not consider the one or two month delay as significant. He currently models Bryhali sales of $17M in 2019, and peak sales of approximately $75M. Maris keeps an Underperform rating on shares of Bausch Health, which are trading up 4% to $27.37 in early trading.
https://thefly.com/landingPageNews.php?id=2801019